Drug Profile
PEP 001
Latest Information Update: 26 Oct 2005
Price :
$50
*
At a glance
- Originator Peplin
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Actinic keratosis; Skin cancer
Most Recent Events
- 01 Apr 2003 Discontinued - Phase-I for Skin cancer in Australia (unspecified route)